BioMarin Looking To Break Even Despite Kyndrisa Uncertainty
This article was originally published in The Pink Sheet Daily
Biotech says it will come out of debt in 2017 even if the Duchenne muscular dystrophy drug is not approved in Europe this year, and looks ahead to a number of pipeline milestones.
You may also be interested in...
FDA wants another clinical trial for Duchenne muscular dystrophy treatment; focus moves to Sarepta's candidate, which gets committee review next week.
American Injectables plans to build up its US-based manufacturing after securing a commitment for $10m of ‘Series A’ financing from New Rhein Healthcare Investors, which it will use to scale up production and launch several generic parenteral products.
A draft EU guideline explains how disease registries can be used to supplement evidence in the pre-authorization phase and provide infrastructure for post-authorization evidence generation.